Evidence-based recommendations on eptinezumab (VYEPTI) for preventing migraine in adults.
Commercial arrangement
There is a simple discount patient access scheme for eptinezumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact United...
Evidence-based recommendations on cannabidiol (Epidyolex) for treating seizures caused by tuberous sclerosis complex.
Commercial arrangement
There is a simple discount patient access scheme for cannabidiol. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS orga...
Evidence-based recommendations on polatuzumab vedotin (Polivy) with rituximab, cyclophosphamide, doxorubicin and prednisolone for untreated diffuse large B-cell lymphoma in adults.
Commercial arrangement
There is a simple discount patient access scheme for polatuzumab vedotin. NHS organisations can get ...
Evidence-based recommendations on endoluminal gastroplication for gastro-oesophageal reflux disease. This involves an endoscopic fastening device being inserted through the mouth and into the stomach, along with an endoscope for constant visualisation. The device is used to attach the fundus to the anter...
Zeng, Mei;
Xia, Jun;
Zong, Zhiyong;
Shi, Yi;
Ni, Yuxing;
Hu, Fupin;
Chen, Yijian;
Zhuo, Chao;
Hu, Bijie;
Lv, Xiaoju;
Li, Jiabin;
Liu, Zhengyin;
Zhang, Jing;
Yang, Wenjie;
Yang, Fan;
Yang, Qiwen;
Zhou, Hua;
Li, Xin;
Wang, Jianhua;
Li, Yimin;
Wang, Minggui.
The dissemination of carbapenem-resistant Gram-negative bacilli (CRGNB) is a global public health issue. CRGNB isolates are usually extensively drug-resistant or pandrug-resistant, resulting in limited antimicrobial treatment options and high mortality. A multidisciplinary guideline development group cov...
NICE is unable to make a recommendation on mitapivat (Pyrukynd) for treating pyruvate kinase deficiency in adults because Agios did not provide an evidence submission. We will review this decision if the company decides to make a submission....
NICE is unable to make a recommendation on teclistamab (Tecvayli) for treating relapsed or refractory multiple myeloma after 3 or more therapies in adults. This is because Agios did not provide an evidence submission. We will review this decision if the company decides to make a submission....
Evidence-based recommendations on vutrisiran (Amvuttra) for treating hereditary transthyretin-related amyloidosis in adults.
Commercial arrangement
There is a simple discount patient access scheme for vutrisiran. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NH...
Evidence-based recommendations on regorafenib (Stivarga) for previously treated metastatic colorectal cancer in adults.
Commercial arrangement
There is a simple discount patient access scheme for regorafenib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS or...
This guideline covers monitoring, treatment and follow-up for people aged 18 and over with Barrett’s oesophagus and stage 1 oesophageal adenocarcinoma. It includes advice on endoscopic and non-endoscopic techniques. It aims to improve outcomes by ensuring the most effective investigations and treatment...
